$SBFM

Sunshine Biopharma (NASDAQ: SBFM) reported that its K1.1 mRNA therapy showed tumor-suppressing activity in liver cancer models. The company plans to combine it with a cancer vaccine to treat non-small cell lung cancer (NSCLC), aiming to convert 'cold' tumors into 'hot' tumors. The K1.1 mRNA targets a tumor suppressor frequently mutated in lung, pancreatic, and liver cancers.

Sunshine Biopharma (SBFM) reported that its K1.1 mRNA lipid nanoparticle showed tumor-suppressing activity in liver cancer mouse models. The company plans to test the mRNA with a cancer vaccine in non-small cell lung cancer (NSCLC). SBFM's stock declined 6.14% following the announcement, trading at $1.07 with heavy volume.

Sunshine Biopharma (SBFM) received Canadian approval for its generic Enalapril tablets, entering the antihypertensive drug market. The company plans to launch 12 more drugs in 2026 and expects shipments by year-end. The global antihypertensive market is projected to grow to $37.24B by 2034. SBFM shares rose 1.79% in premarket trading.

Sunshine Biopharma Inc. (NASDAQ:SBFM) said it launched generic amoxicillin in Canada and began shipping to pharmacies this week in multiple dosages and strengths. The company cited 2025 global amoxicillin sales of about $4.9B, projected to reach about $6.4B by 2031. It also noted its Canadian portfolio includes 60 drugs on market.

Sunshine Biopharma Inc. (NASDAQ:SBFM) said it received Canadian regulatory approval to market its 2mg generic Dienogest tablets for first-line treatment of endometriosis-related pelvic pain. Distribution will be handled by its wholly owned Canadian subsidiary, Nora Pharma. The company expects retail pharmacy shipments by end-2026. Shares rose 6.84% premarket to $1.25.

Sunshine Biopharma Inc. (NASDAQ:SBFM) said it received Canadian regulatory approval for its 2mg generic Dienogest tablets for first-line treatment of pelvic pain from endometriosis. Distribution will be through its wholly owned Nora Pharma. Management expects retail shipments by end-2026. The article also notes a June one-for-ten reverse split and recent approval for generic ondansetron.

Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 sunshine_ex1001.htm AT-THE-MARKET ISSUANCE SALES AGREEMENT, Exhibit 10.1 AT-THE-MARKET ISSUANCE SALES AGREEMENT July 20, 2026 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentlemen: Sunshine Biopharma Inc., a Colorado corpora

Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 sunshine_ex1001.htm RELEASE AGREEMENT Exhibit 10.1 AGREEMENT OF TRANSACTION AND MUTUAL RELEASE Between: Malek Chamoun , domiciled at XXXXXXXXXX (hereinafter “ Chamoun ”) And: Sunshine Biopharma inc ., having a place of business at 1565 Lionel-Boulet boulevard, Varennes,

Sunshine Biopharma Inc. (SBFM) shares rose about 66% pre-market on June 2, 2026, after a 1-for-10 reverse stock split took effect June 1. The company also said Health Canada approved its generic rivaroxaban tablets (2.5mg, 10mg, 15mg, 20mg), with pharmacy shipments expected to start in October 2026 via Nora Pharma.

Sunshine Biopharma (NASDAQ:SBFM) shares fell 5.17% to $0.30 in after-hours trading after the company announced a one-for-ten reverse stock split effective at the market open June 1, 2026. The firm said the move is to regain Nasdaq’s minimum bid-price compliance and expects shares outstanding to drop from 21.24 million to about 2.12 million.